Group 1: Wealth Management Business - The company focuses on high-quality development and digital transformation in wealth management, emphasizing high-quality client groups and efficient online operations [2] - It aims to enhance its asset allocation capabilities and improve the comprehensive service system for institutional clients [2] - The company is committed to compliance and risk management, ensuring that operations are conducted within regulatory boundaries [2] Group 2: Investment Management Business - The investment management segment includes asset management, public fund management, and private fund management, with a focus on building a diverse product supply system [3] - As of September 2025, the public fund management scale of Guangfa Fund and E Fund ranks third and first in the industry, respectively, excluding money market funds [3] - The company is enhancing its research and management capabilities to optimize its business structure [3] Group 3: Derivatives and Investment Banking - The company is a primary dealer in the OTC derivatives market, focusing on pricing, trading, and client service capabilities [3] - It aims to support the real economy and enhance direct financing services while strengthening its position in key markets like the Greater Bay Area and Yangtze River Delta [3] - The company is advancing its digital transformation and risk management strategies to ensure stable development [4]

Investment Rating - The industry investment rating is "Overweight" [5] Core Views - The supply-side reform in the securities industry continues, with ongoing optimization of the industry structure. The merger of CICC with Dongxing Securities and Xinda Securities is expected to enhance the competitive landscape and accelerate the creation of a top-tier investment bank [2] - Following the merger, CICC's financial metrics are projected to improve significantly, with total assets reaching 1 trillion yuan and net assets increasing to 174.7 billion yuan, elevating its ranking among listed securities firms [3] - The brokerage and asset management capabilities of CICC are anticipated to strengthen post-merger, with revenue expected to rise to 27.39 billion yuan and net profit to 9.52 billion yuan, positioning it favorably in the market [3] - There is a mismatch between profitability and valuation in the brokerage sector, with an annualized ROE of 8.2% and a PB valuation of 1.41x, indicating substantial room for valuation recovery [4] Summary by Sections - **Merger Details**: CICC announced a stock swap to absorb Dongxing and Xinda Securities, with trading suspension expected to last no more than 25 trading days [2] - **Financial Impact**: Post-merger, CICC's total asset scale is projected to reach 1 trillion yuan, moving it from the 6th to the 4th position among listed brokers [3] - **Market Positioning**: The merger is expected to enhance CICC's revenue and profit rankings, with significant regional synergies from the combined brokerage networks [3] - **Valuation Insights**: The current valuation of the brokerage sector is seen as misaligned with its fundamentals, suggesting potential for recovery, particularly through this merger [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )及中國報章刊發的《廣發証券股份有限公司關 於召開2025年第二次臨時股東大會的提示性公告》。茲載列如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2025年11月21日 广发证券股份有限公司（以下简称"公司"或"本公司"）已于2025年11月 7日在《中国证券报》《证券时报》《上海证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）披露了《广发证券股份有限公司关于召开2025年第二次临 时股东大会的通知 ...

Group 1: Financial Performance - The company's Q3 2025 net profit increased by over 100% compared to the same period last year, driven by cost reduction and efficiency improvements [3] - The rolling month-on-month growth rate of non-recurring net profit also exceeded 100% [2] - Improved collection of accounts receivable and a reduction in financing interest contributed to the profit increase [3] Group 2: Business Development - The company is actively expanding its heat and power supply business, particularly in the northern regions, with an annual supply of approximately 200,000 tons of steam [3] - New projects in development include Liangshan Shengyuan, Putian Shengyuan, Caoxian Shengyuan, Anhui Shengyuan, and Jiangsu Shengyuan, expected to be operational by 2026 and 2027 [3] Group 3: Technological Advancements - The company is piloting an AI smart combustion system, which is expected to significantly reduce labor costs and save on environmental materials [4] - Currently, three out of 27 production lines are testing the smart combustion control system, with plans to expand to other lines by the end of November 2025 [4] Group 4: Waste Management and Resource Utilization - The company has a waste incineration design capacity of approximately 1.8 million tons per day, with an operational scale of about 1.5 million tons per day [4] - There are currently eight projects (with a waste processing capacity of 5,450 tons per day) that meet the criteria for inclusion in the national subsidy directory [5] Group 5: Investment and Future Prospects - The company has invested in the Moer Thread and Muxi Integrated Circuit, with expected positive contributions to overall investment returns upon their successful listing [7] - The company has received multiple national subsidy payments, which have positively impacted profits and are reflected in the Q3 report [6]

证券代码：000776 证券简称：广发证券 公告编号：2025-046 广发证券股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广发证券股份有限公司（以下简称"公司"或"本公司"）已于2025年11 月7日在《中国证券报》《证券时报》《上海证券报》《证券日报》和巨潮资讯 网（www.cninfo.com.cn）披露了《广发证券股份有限公司关于召开2025年第二 次临时股东大会的通知》。 由于本次股东大会采取现场投票与网络投票相结合的方式，还将通过深圳证 券交易所交易系统和互联网向A股社会公众股股东提供网络形式的投票平台。根 据相关规定，现再次将公司2025年第二次临时股东大会有关事项通知如下： 特别提示： 本通知按照《深圳证券交易所股票上市规则》要求编制，H股股东参加本次 临时股东大会，请参见广发证券股份有限公司（以下简称"广发证券""本公司" 或"公司"）于香港联合交易所有限公司（以下简称"香港联交所"）披露易网 站（www.hkexnews.hk）及本公司网站（www.gf.com.cn）向H ...

Group 1: Computer Industry Outlook - The computer industry is expected to focus on domestic demand TOB direction, including domestic computing power such as chips, servers, and EDA, as well as ERP and industrial software applications like intelligent manufacturing [1] - Positive changes in social financing and manufacturing sector loans are anticipated to support future expenditures [1] - The industry has shown relatively flat performance recently, but forward-looking indicators suggest limited impact from short-term market environment and risk preferences [1] Group 2: Downstream Expenditure Trends - ERP and intelligent manufacturing applications faced challenges in revenue growth due to order release rhythm affected by tariffs, but recent PMI and social financing indicators show positive changes [1] - An expected recovery in downstream expansion is anticipated in the next 1-2 quarters compared to the same period last year [1] - PMI indices for high-tech manufacturing, equipment manufacturing, and consumer goods are in the expansion zone, indicating better revenue performance for related software technology and application companies in Q4 to Q1 [1] Group 3: AI Field Developments - The growth in Token usage for AI models is significant, with enterprise subscriptions, API calls, and process agent integrations generating commercial revenue, particularly in code generation and research [2] - However, challenges remain in commercializing AI applications, with limited scenarios for revenue generation and potential fluctuations in investment pace [2] Group 4: EDA Sector Insights - New export restrictions have negatively impacted IP business performance for companies like Synopsys, disrupting design launches in China and contributing to market weakness [3] - Wuhan Xinxin's IPO plans to raise 4.8 billion yuan, with a significant portion allocated for expanding 12-inch integrated circuit manufacturing, aligning with expectations of increased EDA demand [3] Group 5: AI in Pharmaceutical Sector - Crystal Technology announced the successful development of two new topical ingredients through its AI R&D platform, marking a shift from traditional pharmaceutical collaborations to consumer health products [4] - As a molecular IP holder, the company will receive double-digit sales shares, providing funding support for future consumer health product development [4]

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Core Viewpoint - The investment landscape is shifting from "single product selection" to "platform selection," emphasizing the efficiency of asset allocation and long-term wealth preservation for investors seeking certainty [1] Regulatory Environment - The China Securities Regulatory Commission's 2025 action plan aims to establish a classification evaluation mechanism for fund sales institutions and reduce subscription and service fees, promoting a transition from a "fast" to a "deep cultivation" approach in the industry [1] Platform Strategy - Major distribution platforms are adjusting their strategies to focus on long-term returns and user experience rather than short-term gains, leading to diversified competition that includes advisory services, digital tools, and content ecosystems [1] Comparative Analysis of Fund Sales Platforms - The analysis includes nine representative fund sales institutions categorized into three core groups: third-party platforms (Ant Wealth, Tencent Licai Tong, and Tiantian Fund), bank-affiliated platforms (China Merchants Bank, Industrial and Commercial Bank of China, and Ping An Bank), and brokerage platforms (CITIC Securities, Huatai Securities, and GF Securities) [1] User Demand Analysis - The KANO model is utilized to analyze user needs across fund sales apps, categorizing them into five levels: basic, expected, attractive, indifferent, and reverse needs, highlighting the non-linear relationship between product performance and user satisfaction [2] Third-Party Platforms - Ant Wealth excels in attractive features, while Tencent Licai Tong offers limited advisory services. Tiantian Fund has the most comprehensive product offerings, catering to experienced investors [4] - Ant Wealth provides robust educational and community features, while Tiantian Fund allows users to filter funds based on specific criteria. Tencent Licai Tong lags in the richness of professional tools [4] Bank Platforms - China Merchants Bank stands out in expected needs by offering asset allocation reports, while Industrial and Commercial Bank of China relies on its offline network but shows slower innovation in response to younger, online investors [5] - Ping An Bank utilizes an intelligent risk assessment system to recommend products, addressing various user needs effectively [5] Brokerage Platforms - Huatai Securities' Zhangle Wealth integrates research capabilities to offer in-depth market analysis and fund evaluation, while GF Securities' Yitaojin leads in video content and real-time updates, enhancing user engagement [6] - CITIC Securities' Xintou provides personalized advisory services for high-net-worth clients, indicating a shift towards professional service-based revenue models [6]

Core Insights - The investment landscape is shifting from "single product selection" to "platform selection," emphasizing the importance of asset allocation efficiency and long-term wealth preservation [1] - Regulatory changes are reshaping the industry, with the China Securities Regulatory Commission's 2025 action plan promoting a transition from a "fast" to a "deep cultivation" approach in public fund development [1] - Major distribution platforms are adjusting their strategies to focus on long-term returns and user experience rather than short-term gains, leading to a more diversified competitive landscape [1] Group 1: Platform Positioning and User Satisfaction - The KANO model is utilized to analyze user needs in fund sales apps, categorizing them into five levels: basic, expected, attractive, indifferent, and reverse needs [2] - Ant Financial's wealth management platform excels in attractive features, while Tencent's wealth management service offers limited advisory services [3][4] - Among third-party platforms, Ant Financial meets basic user expectations for "anytime, anywhere investment," while Tiantian Fund offers the most comprehensive product range [4] Group 2: Bank Platforms - Bank platforms excel in basic and expected needs, leveraging strong offline networks and comprehensive financial services, but are relatively conservative in innovation [5] - China Merchants Bank stands out in expected needs by providing asset allocation reports, while Industrial and Commercial Bank of China (ICBC) relies on a combination of online and offline services [5] - Ping An Bank utilizes intelligent risk assessment systems to recommend products, catering to different user segments with tailored services [5] Group 3: Brokerage Platforms - Brokerage platforms like Huatai Securities' Zhangle Wealth and GF Securities' Easy to Invest leverage deep market understanding and research capabilities, targeting stock investors and professional clients [6] - Zhangle Wealth integrates professional research to offer in-depth market analysis, while Easy to Invest excels in live video content and short video updates, enhancing user engagement [6] - The future challenge for brokerages lies in transitioning from a fee-based sales model to a service-oriented advisory model, which will determine their competitiveness in attracting the next generation of investors [6]

Economic Indicators - The Shanghai Composite Index closed up 0.18% at 3946.74 points, while the Shenzhen Component remained flat and the ChiNext Index rose 0.25%[1] - The Hang Seng Index fell 0.38% to 25830.65 points, with the Hang Seng Tech Index down 0.69% and the Hang Seng China Enterprises Index down 0.26%[1] - The U.S. Dow Jones increased by 0.1%, the S&P 500 rose 0.38% to 6642.16 points, and the Nasdaq gained 0.59%[1] Federal Reserve Insights - The Federal Reserve's October meeting minutes indicated that many officials oppose a rate cut in December, suggesting that maintaining rates may be appropriate for the remainder of the year[12] - Market traders have reduced the probability of a rate cut by the end of the year to approximately 30%[8] Corporate Developments - China International Capital Corporation (CICC) plans to absorb and merge with Dongxing Securities and Xinda Securities, resulting in a combined registered capital of 11.3 billion RMB (approximately 1.6 billion USD)[8] - Nvidia reported a 62% increase in revenue for Q3, with a forecast of approximately 65 billion USD for the upcoming quarter, exceeding analyst expectations[12]